xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.23262, Wiley Online Library on [02/01/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

446

KUANetal.

1841. Pierpont TM, Limper CB, Richards KL. Past, present, and future of rituximab-the world’s first oncology monoclonal antibody therapy. Front Oncol . 2018;8(163):163. https://doi.org/ 10.3389/fonc.2018.00163 1842. Bennett CL, Focosi D, Socal MP, et al. Progressive multifo cal leukoencephalopathy in patients treated with rituximab: a 20-year review from the Southern Network on Adverse Reac tions. Lancet Haematol . 2021;8(8):e593-e604. https://doi.org/ 10.1016/S2352-3026(21)00167-8 1843. Vahamurto P, Mannisto S, Pollari M, Karjalainen-Lindsberg ML, Makitie AA, Leppa S. Clinical features and outcome of the patients with sinonasal tract diffuse large B-cell lymphoma in the pre-rituximab and rituximab eras. Eur J Haematol . 2019;102(6):457-464. https://doi.org/10.1111/ejh.13225 1844. Brown HJ, Varelas EA, Ganti A, et al. Prognostic indicators of survival in sinonasal diffuse large B-cell lymphoma: a national cancer database analysis. Laryngoscope . 2022;132(8):1515-1522. https://doi.org/10.1002/lary.29864 1845. Ribrag V, Hajj ME, Janot F, et al. Early locoregional high dose radiotherapy is associated with long-term disease control in localized primary angiocentric lymphoma of the nose and nasopharynx. Leukemia . 2001;15(7):1123-1126. https://doi.org/ 10.1038/sj.leu.2402148 1846. Lehrich BM, Goshtasbi K, Abiri A, et al. Treatment modalities and overall survival outcomes for sinonasal extranodal natural killer/T-cell lymphoma. Leuk Lymphoma . 2021;62(3):727-730. https://doi.org/10.1080/10428194.2020.1834097 1847. Gupta VG, Gogia A, Kumar L. Combined modality treat ment with “dexamethasone, methotrexate, ifosfamide, l asparaginase, and etoposide” chemotherapy and involved field radiotherapy for early stage natural Killer/T cell lym phoma with local tumor invasiveness: a single-institution study from India. Indian J Med Paediatr Oncol . 2018;39(1):67 72. 1848. Yi W, Yang T, Lin S, et al. New approaches for treatment of advanced extranodal NK/T-cell lymphoma. Cancer Manag Res . 2022;14:401-407. https://doi.org/10.2147/CMAR.S328846 1849. Coha B, Vucinic I, Mahovne I, Vukovic-Arar Z. Extra nodal lymphomas of head and neck with emphasis on NK/T-cell lymphoma, nasal type. J Craniomaxillofac Surg . 2014;42(2):149-152. https://doi.org/10.1016/j.jcms.2013.04.004 1850. Guo Y, Lu JJ, Ma X, et al. Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lym phoma: elucidating the significance of systemic chemother apy. Oral Oncol . 2008;44(1):23-30. https://doi.org/10.1016/j. oraloncology.2006.11.020 1851. Kim GE, Koom WS, Yang WI, et al. Clinical relevance of three subtypes of primary sinonasal lymphoma characterized by immunophenotypic analysis. HeadNeck . 2004;26(7):584-593. https://doi.org/10.1002/hed.20015 1852. Lee J, Park YH, Kim WS, et al. Extranodal nasal type NK/T cell lymphoma: elucidating clinical prognostic factors for risk based stratification of therapy. Eur J Cancer . 2005;41(10):1402 1408. https://doi.org/10.1016/j.ejca.2005.03.010 1853. Ma HH, Qian LT, Pan HF, et al. Treatment outcome of radio therapy alone versus radiochemotherapy in early stage nasal natural killer/T-cell lymphoma. Med Oncol . 2010;27(3):798 806. https://doi.org/10.1007/s12032-009-9288-7

and: important mediators of tissue damage. Histopathology . 1997;31(5):444-450. 1829. Suzumiya J, Takeshita M, Kimura N, et al. Expression of adult and fetal natural killer cell markers in sinonasal lymphomas. Blood . 1994;83(8):2255-2260. 1830. Zhiyan D, Caihong H, Jiajia Y. Clinical pathological anal ysis of nasal natural Killer/T-cell lymphoma patients. Can cer Res Clin . 2018;30(3):193-196. https://doi.org/10.3760/cma.j. issn.1006-9801.2018.03.012 1831. Li ZM, Zhu YJ, Sun J, et al. Serum beta2-microglobin is a predictor of prognosis in patients with upper aerodigestive tract NK/T-cell lymphoma. Ann Hematol . 2012;91(8):1265 1270. https://doi.org/10.1007/s00277-012-1434-1 1832. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemother apy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol . 2006;7(5):379-391. https://doi.org/10.1016/S1470 2045(06)70664-7 1833. Oprea C, Cainap C, Azoulay R, et al. Primary diffuse large B cell non-Hodgkin lymphoma of the paranasal sinuses: a report of 14 cases. Br J Haematol . 2005;131(4):468-471. https://doi.org/ 10.1111/j.1365-2141.2005.05787.x 1834. Laskin JJ, Savage KJ, Voss N, Gascoyne RD, Connors JM. Primary paranasal sinus lymphoma: natural history and improved outcome with central nervous system chemopro phylaxis. Leuk Lymphoma . 2005;46(12):1721-1727. https://doi. org/10.1080/17402520500182345 1835. Varelas AN, Eggerstedt M, Ganti A, Tajudeen BA. Epidemi ologic, prognostic, and treatment factors in sinonasal diffuse large B-cell lymphoma. Laryngoscope . 2019;129(6):1259-1264. https://doi.org/10.1002/lary.27639 1836. Lee GW, Go SI, Kim SH, et al. Clinical outcome and prog nosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: a study by the Consortium for Improving Survival of Lym phoma. Leuk Lymphoma . 2015;56(4):1020-1026. https://doi. org/10.3109/10428194.2014.946027 1837. Cooper DL, Ginsberg SS. Brief chemotherapy, involved field radiation therapy, and central nervous system prophylaxis for paranasal sinus lymphoma. Cancer . 1992;69(12):2888-2893. https://doi.org/10.1002/1097-0142(19920615)69:12 ⟨ 2888::aid cncr2820691205 ⟩ 3.0.co;2-d 1838. Hausdorff J, Davis E, Long G, et al. Non-Hodgkin’s lymphoma of the paranasal sinuses: clinical and pathological features, and response to combined-modality therapy. Cancer J Sci Am . 1997;3(5):303-311. 1839. Steele TO, Buniel MC, Mace JC, El Rassi E, Smith TL. Lym phoma of the nasal cavity and paranasal sinuses: a case series. Am J Rhinol Allergy . 2016;30(5):335-339. https://doi.org/10. 2500/ajra.2016.30.4347 1840. Han AY, Kuan EC, Alonso JE, Badran KW, St John MA. Epidemiology of nasopharyngeal lymphoma in the United States: a population-based analysis of 1119 cases. Otolaryngol Head Neck Surg . 2017;156(5):870-876. https://doi.org/10.1177/ 0194599817695808